Dr. Kelly is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1025 Walnut St
Ste 700
Philadelphia, PA 19107- Is this information wrong?
Summary
- Dr. William Kelly is a genitourinary oncologists with over 30 years of experience treating patients with prostate cancer, testicular cancer, bladder cancer and kidney cancer. He is affiliated with Thomas Jefferson University and the Sidney Kimmel Cancer Center.
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
- Albert Einstein Healthcare NetworkResidency, Internal Medicine, 1987 - 1990
- Philadelphia College of Osteopathic MedicineClass of 1986
Certifications & Licensure
- DE State License 2017 - 2025
- NY State License 1990 - 2025
- NJ State License 2017 - 2025
- PA State License 1987 - 2024
- CT State License 2005 - 2011
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer Start of enrollment: 1998 Apr 01
- Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy Start of enrollment: 2000 Jan 01
- Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer Start of enrollment: 2000 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance).Jai N Patel, Chen Jiang, Kouros Owzar, Daniel L Hertz, Janey Wang, Flora A Mulkey, William K Kelly, Susan Halabi, Yoichi Furukawa, Cameron Lassiter, Susan G Dorsey, Pa...> ;The Pharmacogenomics Journal. 2024 Mar 4
- TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing.Stacy Loeb, Scott W Keith, Heather H Cheng, Amy E Leader, Laura Gross, Tatiana Sanchez Nolasco, Nataliya Byrne, Rebecca Hartman, Lauren H Brown, Christopher Michael Pi...> ;JCO Precision Oncology. 2024 Mar 1
- 2 citationsXaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.Kelly, W., Danila, D., Lin, C., Lee, J., Matsubara, N., Ward, P., Armstrong, A., Pook, D., Kim, M., Dorff, T., Fischer, S., Lin, Y., Horvath, L., Sumey, C., Yang, Z., ...> ;Cancer Discovery. 2024 Jan 12
- Join now to see all
Journal Articles
- Germline Genetic Testing for Inherited Prostate Cancer in Practice: Implications for Genetic Testing, Precision Therapy, and Cascade TestingColette Hyatt, William K Kelly, Veda N Giri, Leonard G Gomella, Karen E Knudsen, The Prostate
Press Mentions
- Thomas Jefferson University Appoints Chair of Medical OncologyJanuary 22nd, 2023
Grant Support
- Development Of Oral Suberoylanilide Hydroxamic AcidNational Cancer Institute2002–2003
Professional Memberships
- Member
- Member
Hospital Affiliations
- Thomas Jefferson University HospitalPhiladelphia, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: